Form 144 Replimune Group Inc. For: 20 November
- Investing.com
Market Dynamics | Learn how Replimune navigates the competitive oncology landscape, leveraging its unique technology to differentiate itself in a growing biotech secto |
Financial Outlook | Delve into Replimune's financial stability amidst negative EPS projections, with analysts setting an average price target of $8.60 per share |
Pipeline Potential | Explore Replimune's ongoing clinical trials and expansion opportunities for RP1 in various cancer indications, showcasing the company's innovative approach |
Regulatory Hurdles | Replimune faces FDA challenges for RP1 in melanoma treatment, impacting stock performance and future prospects in oncology therapies |
Metrics to compare | REPL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipREPLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.7x | −1.8x | −0.2x | |
PEG Ratio | −0.34 | −0.05 | 0.00 | |
Price / Book | 8.8x | 2.4x | 2.6x | |
Price / LTM Sales | - | 8.4x | 2.6x | |
Upside (Analyst Target) | 33.7% | 136.3% | 76.9% | |
Fair Value Upside | Unlock | 18.6% | 14.9% | Unlock |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.